extract: 2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review

Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>

domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md

@@ -46,6 +46,12 @@ ARISE report reframes OpenEvidence adoption as shadow-IT workaround behavior rat
 
 Sutter Health (3.3M patients, ~12,000 physicians) integrated OpenEvidence into Epic EHR workflows in February 2026, marking the first major health-system-wide EHR embedding. This shifts OpenEvidence from standalone app to in-workflow clinical tool, institutionalizing what ARISE identified as physicians bypassing institutional IT governance.
 
+### Additional Evidence (extend)
+*Source: [[2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review]] | Added: 2026-03-24*
+
+iatroX reports OE has 'signalled plans for global expansion as a key 2026 and beyond initiative' with UK, Canada, Australia identified as 'English-first markets with lower regulatory barriers.' However, iatroX notes this perception may be inaccurate for UK: NHS requires DTAC + MHRA Class 1 for formal deployment. OE's characterization of UK as having 'lower regulatory barriers' relative to US may be a strategic misjudgment—UK NHS has MORE formal digital health procurement governance than US (no federal equivalent to DTAC).
+
+
 
 
 

domains/health/healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software.md

@@ -19,6 +19,12 @@ The AI payment problem compounds the regulatory gap. No payer currently reimburs
 
 ---
 
+### Additional Evidence (extend)
+*Source: [[2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review]] | Added: 2026-03-24*
+
+UK NHS governance provides a contrasting model: DTAC (Digital Technology Assessment Criteria) + MHRA Class 1 registration + NICE Evidence Standards Framework creates a multi-layer assessment specifically for digital health tools. NHS England launched a supplier registry in January 2026 with 19 registered ambient voice transcription suppliers, all DTAC-compliant. This demonstrates an alternative regulatory approach to AI clinical tools that is more comprehensive than FDA's device-focused model.
+
+
 Relevant Notes:
 - [[the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification]] -- the FDA has already created flexibility for wellness devices; clinical AI needs a parallel regulatory innovation
 - [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] -- AI payment gaps may accelerate VBC adoption by making fee-for-service untenable for AI-enabled care

inbox/queue/.extraction-debug/2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review.json

@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "openevidence-us-corpus-creates-uk-clinical-safety-risk-through-guideline-mismatch.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "openevidence-us-corpus-creates-uk-clinical-safety-risk-through-guideline-mismatch.md:set_created:2026-03-24"
+    ],
+    "rejections": [
+      "openevidence-us-corpus-creates-uk-clinical-safety-risk-through-guideline-mismatch.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-24"
+}

inbox/queue/2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review.md

@@ -7,9 +7,13 @@ date: 2026-03-20
 domain: health
 secondary_domains: []
 format: blog-analysis
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [openevidence, nhs-dtac, nice-esf, uk-healthcare, clinical-ai-safety, belief-5, regulatory-compliance, corpus-bias]
+processed_by: vida
+processed_date: 2026-03-24
+enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -70,3 +74,11 @@ iatroX Clinical AI Insights is a UK-focused clinical AI review publication that
 PRIMARY CONNECTION: OE model opacity thread (Sessions 8-11) — extended to UK clinical corpus mismatch
 WHY ARCHIVED: Provides a previously undocumented clinical risk category for OE in non-US markets: guideline mismatch, not just LLM failure modes
 EXTRACTION HINT: Extract as "OE UK deployment risk" claim, keeping scope to UK clinical practice (NICE vs. AHA corpus misalignment); link to DTAC absence finding
+
+
+## Key Facts
+- NHS England launched ambient scribing supplier registry in January 2026 with 19 registered vendors
+- NHS England's April 2025 ambient scribing guidance requires clinical safety case (DCB0160), DPIA, mandatory human verification
+- DTAC V2 deadline was April 6, 2026
+- OpenEvidence Visits launched August 2025 as hybrid documentation+CDSS tool
+- UK-native DTAC-compliant alternatives include: iatroX, Medwise AI, Praktiki, Pathway